Accès ouvert
2026
article
OpenAlex
Óscar Moreno-Pérez, Antonio Tejera-Muñoz, Nuria Leiva-Mora, Elisa Gonzalez Santacruz et autres
BACKGROUND: Current guidelines recommend baseline insulin as the standard treatment for most people hospitalised with type 2 diabetes (PWT2D). However, they generally discourage the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists due to safety concerns and …
es
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Óscar Moreno, Antonio Tejera‐Muñoz, Rubén Carreño-Valdivia, María Rodríguez-Bedoya et autres
BACKGROUND: Evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on serum urate (SU) levels in people with type 2 diabetes (PWT2D) is limited. This study investigates the effect of oral semaglutide on SU levels. METHODS: Retrospective, observational study including …
es
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
María Rodríguez-Bedoya, Rubén Carreño-Valdivia, Cristina Guillén-Morote, Alicia Tejera et autres
Background: Gout is the most common inflammatory arthritis among adults and is associated with an increased risk of cardiovascular disease, kidney failure, and all-cause mortality. There is limited evidence regarding the effect of glucagon-like peptide-1 (GLP-1) receptor agonists on serum urate (SU) …
es
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Óscar Moreno, Cristina Guillén-Morote, Thalía Argüello, Carmen Soriano et autres
Abstract Disclosure: O. Moreno-Perez: None. C. Guillen-Morote: None. T. Argüello: None. C. Soriano: None. E. SantaCruz: None. P. Lopez-Mondejar: None. C. Navarro-Hoyas: None. R. Sanchez-Ortiga: None. M. Sanchez-Pacheco: None. I. Modrego-Pardo: None. A.M. Pico: None. Introduction: Oral semaglutide (oSEMA) is the first …
es
(code pays fourni par la source)